New treatment guidelines for unstable angina/non-ST-segment elevation myocardial infarction

Annals of Pharmacotherapy

Volumn 36, Issue 11, 2002, Pages 1800-1804

  Howard, Patricia A ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; DALTEPARIN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; GEMFIBROZIL; HEPARIN; NADROPARIN; PLACEBO; TICLOPIDINE; TINZAPARIN; TIROFIBAN;

BLEEDING; BLEEDING TIME; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY BYPASS GRAFT; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HEART INFARCTION; HUMAN; MEDICAL SOCIETY; NEUTROPENIA; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; ST SEGMENT ELEVATION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0036841506     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C274     Document Type: Review

References (24)

1. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA 2002 Guideline Update for the Management of Patients with Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). 2002 [cited 2002 Oct 1]. Available from: URL:http://www.acc.org/clinical/guidelines/ unstable/unstable.pdf.
2. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, Investigators FT. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. Circulation 2000;102:624-9.
3. Bennett CL, Connors JM, Carwile JM, Moake JL, Bell WR, Tarantolo SR, et al. Thrombotic thrombocytopenia purpura associated with clopidogrel. N Engl J Med 2000;342:1773-7.
4. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PR, Kwaan HC, Green D. Thrombotic thrombocytopenia purpura associated with ticlopidine: A review of 60 cases. Ann Intern Med 1998;127:541-4.
5. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
6. Mehta SR, Yusuf S, Peters RJG, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001;358:527-33.
7. Gaspoz JM, Coxson PG, Goldman PA, Williams LW, Kuntz KM, Hunink MGM, et al. Cost-effectiveness of aspirin, clopidogrel or both for secondary prevention of coronary heart disease. N Engl J Med 2002;346:1800-6.
8. Khot UN, Nissen SE. Is CURE a cure for acute coronary syndromes? Statistical versus clinical significance. J Am Coll Cardiol 2002;40:218-9.
9. Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization: The GUSTO IV-ACS randomised trial. Lancet 2001;357:1915-24.
10. Boersma E, Harrington RA, Moliterno DJ, White H, Theroux P, Van de Weft F, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials. Lancet 2002;359:189-98.
11. Quinn MJ, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors. Recognition of a two-edged sword? Circulation 2002;106:379-85.
12. Moliterno DJ, Yakubov SJ, DiBattiste PM, Herrmann HC, Stone GW, Macaya C, et al. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization with stent placement: The TARGET follow-up study. Lancet 2002;360: 355-60.
13. Antman EM, Cohen M, Radley D, McCabe C, Rush J, Premmereur J, et al. TIMI (Thrombolysis in Myocardial Infarction) and ESSENCE (Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events) Investigators. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction TIMI 11 B-ESSENCE meta-analysis. Circulation 1999;100:1602-8.
14. Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AG, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin In unstable Coronary artery disease study (FRIC). Circulation 1997;96:61-8. Erratum: Circulation 1998;97: 413.
15. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction. FRAX.I.S. (FRAXiparine in Ischaemic Syndrome). Eur Heart J 1999;20:1553-62.
16. Michalis LK, Papamichail N, Katsouras CS, Karahaliou A, Sourla E, Novas J, et al. Enoxaparin versus tinzaparin in the management of unstable coronary artery disease (EVET Study) (abstract). J Am Coll Cardiol 2001;37:365A.
17. Collet JP, Montalescot G, Lison L, Choussat R, Ankri A, Drobinski G, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001;103:658-63.
18. Kereiakes DJ, Grines C, Fry E, Esente P, Hoppensteadt D, Midei M, et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaenous coronary intervention. J Invasive Cardiol 2001;13:272-8.
19. Ferguson JJ, Antman EM, Bates ER, Cohen M, Every NR, Harrington RA, et al. The use of enoxaparin and IIb/IIIa antagonists in acute coronary syndromes, including PCI: Final results of the NICE-3 study (abstract). J Am Coll Cardiol 2001;37:365A.
20. Kereiakes DJ, Kleiman NS, Fry E, Mwawasi G, Lengerich R, Maresh K, et al. Dalteparin in combination with abciximab during percutaneous coronary intervention (letter). Am Heart J 2001;141:348-52.
21. Cohen M, Theroux P, Frey MJ, White HD, Borzak S, Weber S, et al. Anti-thrombotic combination using tirofiban and enoxaparin: The ACUTE II Study (abstract). Circulation 2000;102(suppl II):II-826.
22. Blazing MA, deLemos JA, Dyke CK, Califf RM, Bilheimer D, Braunwald E. The A-to-Z trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am Heart J 2001;142:211-7.
23. The SYNERGY trial: Study design and rationale. Am Heart J 2002;143: 952-60.
24. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA 2001;285:1711-8.